These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 30338502)
1. Secondary prevention of cardiovascular diseases: current state of the art. Hasenfuß G Kardiol Pol; 2018; 76(12):1671-1679. PubMed ID: 30338502 [TBL] [Abstract][Full Text] [Related]
2. [Secondary cardiovascular prevention after acute coronary syndrome in clinical practice]. Colivicchi F; Di Roma A; Uguccioni M; Scotti E; Ammirati F; Arcas M; Avallone A; Bonaccorso O; Germanò G; Letizia C; Manfellotto D; Minardi G; Pristipino C; D'Amore F; Di Veroli C; Fierro A; Pastorellio R; Tozzi Q; Tubaro M; Santini M; Angelico F; Azzolini P; Bellasi A; Brocco P; Calò L; Cerquetani E; De Biase L; Di Napoli M; Galati A; Gallieni M; Jesi AP; Lombardo A; Loricchio V; Menghini F; Mezzanotte R; Minutolos R; Mocini D; Patti G; Patrizi R; Pajes G; Pulignano G; Ricci RP; Ricci R; Sardella G; Strano S; Terracina D; Testa M; Tomai F; Volpes R; Volterrani M; G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 4):3S-29S. PubMed ID: 20873094 [TBL] [Abstract][Full Text] [Related]
3. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis]. Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811 [TBL] [Abstract][Full Text] [Related]
9. Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. Fitchett DH; Goodman SG; Leiter LA; Lin P; Welsh R; Stone J; Grégoire J; Mcfarlane P; Langer A Can J Cardiol; 2016 Jul; 32(7 Suppl):S15-34. PubMed ID: 27342696 [TBL] [Abstract][Full Text] [Related]
10. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387 [TBL] [Abstract][Full Text] [Related]
11. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH; Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833 [TBL] [Abstract][Full Text] [Related]
12. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials]. Lièvre M Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124 [TBL] [Abstract][Full Text] [Related]
13. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597 [TBL] [Abstract][Full Text] [Related]
14. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M; Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169 [TBL] [Abstract][Full Text] [Related]
15. Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. Kong NW; Bavishi A; Amaral AP; Tibrewala A; Jivan A; Silberman P; Stone NJ Am J Cardiol; 2020 Oct; 133():1-6. PubMed ID: 32807385 [TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular risk factors and prevention in women: similarities and differences]. Sclavo M Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880 [TBL] [Abstract][Full Text] [Related]
17. [Risk Factors and Therapeutic Goals for Primary and Secondary Cardiovascular Prevention: Significance for the Glaucoma Patient]. Hacke C; Erb C; Weisser B Klin Monbl Augenheilkd; 2018 Feb; 235(2):151-156. PubMed ID: 29448285 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. Goderis G; Boland B Acta Clin Belg; 2004; 59(6):329-39. PubMed ID: 15819377 [TBL] [Abstract][Full Text] [Related]
19. Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors. Harris SB; Lank CN Can Fam Physician; 2004 Mar; 50():425-33. PubMed ID: 15318682 [No Abstract] [Full Text] [Related]
20. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]